MyHep All Tablets
Pan-Genotypic Treatment for Chronic Hepatitis C Infection
MyHep All is a modern antiviral medication used for the treatment of chronic Hepatitis C virus (HCV) infection. It combines Sofosbuvir and Velpatasvir, two direct-acting antivirals that work together to stop the hepatitis C virus from replicating in the body.
This combination is effective against all major genotypes of Hepatitis C, making it a preferred first-line option in many treatment guidelines. By eliminating the virus, MyHep All helps improve liver health and significantly reduces the risk of serious complications such as cirrhosis, liver failure, and hepatocellular carcinoma.
MyHep All is known for its high cure rates, simplified once-daily regimen, and good tolerability when used as prescribed. It is suitable for many adults with chronic hepatitis C, including those with or without liver scarring, based on medical evaluation.
Key Benefits
- ✅ Treats all genotypes (1–6) of Hepatitis C
- ✅ High viral clearance and cure rates
- ✅ Helps restore and protect liver function
- ✅ Reduces risk of long-term liver complications
- ✅ Well-tolerated modern antiviral therapy
- ✅ Suitable for first-time or retreatment cases
Who Is It For?
- Adults diagnosed with chronic Hepatitis C infection
- Patients seeking pan-genotypic antiviral therapy
- Individuals aiming to prevent liver damage and complications
- Use under specialist medical supervision
MyHep All represents a major advancement in hepatitis C care — offering patients a real opportunity for cure and long-term liver health.
Prescription-only medicine. Always use under the guidance of a healthcare professional.